Aller au contenu principal
Traduction en cours — ce contenu s’affiche en anglais pendant que votre version dans votre langue est en préparation.
Retour aux discussions

Vasant Narasimhan, PDG de Novartis, sur la transformation d'une entreprise vieille de 250 ans

Business
Global
Commencé February 17, 2026

a16z general partner Jorge Conde talks with Vasant Narasimhan, CEO of Novartis International, about transforming a 250-year-old conglomerate into a pure play medicines company and unlocking $180 billion of value in the process. They cover Novartis's platform technologies: cell and gene therapies, RNA medicines, and radioligand therapies. They also discuss AI in drug discovery, the rise of China as a biotech competitor, and what Vasant looks for when evaluating startup partnerships, including ...

Articles sources

Ajouter une affirmation Analyse 0/5
Need to find a specific claim? Search all statements.
🗳️ Join the conversation
5 affirmations à voter • Your perspective shapes the analysis
📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement
Participants 0/7
Statements (7+ recommended) 5/7
Total Votes 0/20
💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM Publié par will • Feb 17, 2026
Partnerships with startups should focus on long-term collaboration, as short-term gains may lead to unsustainable practices in the biotech industry.

Traduction en attente

Vote options for this statement: agree, disagree, or unsure
💬 Voir la discussion
Be first to respond
Vote to see results
CLAIM Publié par will • Feb 17, 2026
AI's role in drug discovery at Novartis could streamline research processes, but ethical concerns about data use must be addressed.

Traduction en attente

Vote options for this statement: agree, disagree, or unsure
💬 Voir la discussion
Be first to respond
Vote to see results
CLAIM Publié par will • Feb 17, 2026
The focus on high-value therapies may neglect affordable treatments, widening the gap in healthcare access for underserved populations.

Traduction en attente

Vote options for this statement: agree, disagree, or unsure
💬 Voir la discussion
Be first to respond
Vote to see results
CLAIM Publié par will • Feb 17, 2026
Emphasizing cell and gene therapies positions Novartis as a leader in biotech, essential for competing against rising players like China.

Traduction en attente

Vote options for this statement: agree, disagree, or unsure
💬 Voir la discussion
Be first to respond
Vote to see results
CLAIM Publié par will • Feb 17, 2026
Transforming Novartis into a pure play medicines company will drive innovation and significantly enhance patient care worldwide.

Traduction en attente

Vote options for this statement: agree, disagree, or unsure
💬 Voir la discussion
Be first to respond
Vote to see results

💡 How This Works

  • • Add Statements: Post claims or questions (10-500 characters)
  • • Vote: Agree, Disagree, or Unsure on each statement
  • • Respond: Add detailed pro/con responses with evidence
  • • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us